Aridis focuses on anti-infective alternatives to conventional antibiotics


>> More News

Feb 2nd, 2016

Aridis Pharmaceuticals to Present at BIO CEO & Investor Conference 2016.  (More)

Jan 7th, 2016

Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin® for Treating Hospital-Acquired and Ventilator-Associated Pneumonia.  (More)

Jan 6th, 2016

Aridis Pharmaceuticals to Present at Biotech Showcase™ 2016.  (More)

Oct 13th, 2015

Aridis Pharmaceuticals Receives Multiple NIH Grants. (More)

Sep 15th, 2015

Aridis Pharmaceuticals Receives FDA Fast Track Designation for AR-301 for Acute Pneumonia caused by Staphylococcus aureus. (More)

Mining the human immune response for rare monoclonal antibodies to fight infections